SEC Comment Letter 0000000000-23-012582 to OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: Nov. 16, 2023 · CIK: 0001637715 · Accession: 0000000000-23-012582
AI Filing Summary & Sentiment
File numbers found in text: 333-275518
Letter
United States securities and exchange commission logo November 16, 2023 Gregory J. Flesher Chief Executive Officer Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612 Re:Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275518 Dear Gregory J. Flesher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Wade Andrews, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2023
Gregory J. Flesher
Chief Executive Officer
Reneo Pharmaceuticals, Inc.
18575 Jamboree Road, Suite 275-S
Irvine, CA 92612
Re:Reneo Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275518
Dear Gregory J. Flesher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Wade Andrews, Esq.